NCT02220933 - Effect of MD1003 in Spinal Progressive Multiple Sclerosis | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2018

Conditions

Multiple Sclerosis

Interventions

DRUG

MD1003 100mg capsule

DRUG

Placebo

Trial Locations (17)

13000

Hopital de la Timone, Marseille

14000

Hopital de la cote de Nacre, Caen

21000

Hopital general du Bocage, Dijon

31000

Hopital Purpan, Toulouse

33000

Hopital Pellegrin, Bordeaux

34000

Hopital Gui de Chauliac, Montpellier

35000

Hopital Pontchaillou, Rennes

44000

Hopital Nord Laennec, Nantes

51000

Hopital Maison Blanche, Reims

54000

Hopital Central, Nancy

63000

Hopital Gabriel Montpied, Clermont-Ferrand

67000

Hopital Hautepierre, Strasbourg

69000

Hopital Pierre Wertheimer, Lyon

75013

Groupe hospitalier la Pitié-Salpêtrière, Paris

75019

Fondation Rothschild, Paris

78300

Centre hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, Poissy

06000

Hopital Pasteur, Nice